Capone E, Giansanti F, Ponziani S, Lamolinara A, Iezzi M, Cimini A, Angelucci F, Sorda R, Laurenzi V, Natali PG, Ippoliti R, Iacobelli S, Sala G (2017) EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma. Oncotarget 8(56):95412-95424. doi: 10.18632/oncotarget.20728 PMID: 29221137
Objective: Using EV20 (Anti-Her3)-SAP to target Her3 positive melanoma
Summary: Linking a humanized monoclonal antibody targeting Her3, named EV20, to saporin creates a powerful cytotoxic agent targeting melanoma – which overexpress the Her3 receptor. The antibody, EV20, rapidly is internalized by Her3 whether its dependent ligand is there or not. EV20-SAP demonstrated potent and specific cytotoxicity towards human melanoma cells.
Usage: At a concentration of 19 nM only 10% of the human melanoma cells 9 (SK-MEL24 melanoma cells) survived, where free saporin at the same concentration shows no/minimal cytotoxicity.
Related Products: Saporin (Cat. #PR-01)